Cargando…
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
PURPOSE: This first-in-human Phase I study investigated the safety, pharmacokinetics (PK), pharmacodynamic profile, and preliminary efficacy of CC-115, a dual inhibitor of mammalian target of rapamycin (mTOR) kinase and DNA-dependent protein kinase. PATIENTS AND METHODS: Patients with advanced solid...
Autores principales: | Munster, Pamela, Mita, Monica, Mahipal, Amit, Nemunaitis, John, Massard, Christophe, Mikkelsen, Tom, Cruz, Cristina, Paz-Ares, Luis, Hidalgo, Manuel, Rathkopf, Dana, Blumenschein Jr, George, Smith, David C, Eichhorst, Barbara, Cloughesy, Tim, Filvaroff, Ellen H, Li, Shaoyi, Raymon, Heather, de Haan, Hans, Hege, Kristen, Bendell, Johanna C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916675/ https://www.ncbi.nlm.nih.gov/pubmed/31853198 http://dx.doi.org/10.2147/CMAR.S208720 |
Ejemplares similares
-
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
por: Wolin, Edward, et al.
Publicado: (2019) -
CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
por: Tsuji, Toshiya, et al.
Publicado: (2017) -
Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential
por: Bürkel, Felix, et al.
Publicado: (2020) -
An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth
por: Chen, Fagui, et al.
Publicado: (2022) -
CC-115 Mediates GSDME-Dependent Pyroptosis in Lung Adenocarcinoma Through the Akt/Bax Pathway
por: Zhang, Ting, et al.
Publicado: (2023)